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Abstract
Purpose Cyclosporine A (CsA) and imatinib are both
CYP3A4 and P-glycoprotein substrates. Concomitant use af-
ter hematopoietic stem cell transplantation (HSCT) for chron-
ic myeloid leukemia (CML) or Philadelphia chromosome-
positive (Ph+) acute lymphatic leukemia (ALL) may therefore
result in a pharmacokinetic interaction. Although case reports
and a recent small study in children indeed suggested there is a
relevant pharmacokinetic interaction, a larger study in adults
is lacking. In this study, we assessed the presence and extent of
this interaction in patients with CML or Ph+ ALL undergoing
HSCT.
Methods From a large database containing data of all patients
receiving HSCT in our center between 2005 and 2015, we
selected 16 patients using this drug combination. The average
dose-corrected CsA concentration was calculated before and
after initiation of imatinib.
Results The average dose-corrected CsA concentration in-
creased during imatinib use in all patients, on average by
94 % (p < 0.001). Based on measured drug concentrations,
the CsA dosage needed to be reduced, on average, by 27 %
after initiation of imatinib (p = 0.004).
Conclusions Imatinib significantly increases CsA concentra-
tions in HSCT patients, putting these patients at increased risk
of CsA toxicity. We recommend intensive monitoring of CsA
concentrations after initiation of imatinib; a pre-emptive CsA
dose reduction of 25 % might be considered.
Keywords Cyclosporine . Imatinib . Hematopoietic stem cell
transplantation . Graft-versus-host disease
Introduction
Cyclosporine A (CsA) is an immunosuppressive agent with a
narrow therapeutic index, which acts primarily on T-helper
cells [1]. It is one of the cornerstone drugs in the prevention
and treatment of graft-versus-host disease (GvHD) after he-
matopoietic stem cell transplantation (HSCT) [1]. Imatinib is a
tyrosine kinase inhibitor directed against the BCR-ABL fu-
sion enzyme, which is present in chronic myeloid leukemia
(CML) and Philadelphia chromosome-positive acute lym-
phoid leukemia (Ph+ ALL) [2–4]. The drug combination
CsA and imatinib is a possible treatment combination after
HSCT for CML and Ph+ ALL. In these Ph+ leukemias, ima-
tinib is initiated or re-initiated after bone marrow repopulation
to further prevent recurrence of the disease [5]. Both CsA and
imatinib are substrates as well as inhibitors of CYP3A4 and
P-glycoprotein (P-gp) [1, 3]. Therefore, inhibition of CYP3A4
and/or P-gp by imatinib may increase CsA exposure and vice
versa [6, 7]. In view of the narrow therapeutic index of CsA,
and as many patients following HSCT already suffer from
some degree of renal insufficiency, it is important to avoid
supra-therapeutic CsA exposure.
Some case reports showed CsA toxicity during imatinib
use, potentially as a consequence of this interaction [8, 9]. In
a recent case series, a higher CsA exposure was found after 3
to 7 days of imatinib therapy in six children undergoing HSCT
[10]. However, data in adults and recommendations for
* Jorie Versmissen
j.versmissen@erasmusmc.nl
1 Department of Hospital Pharmacy, Erasmus Medical Center,
Rotterdam, The Netherlands
2 Department of Hematology, Erasmus Medical Center,
Rotterdam, The Netherlands
3 Department of Internal Medicine, Erasmus Medical Center, PO Box
2040, 3000, CA Rotterdam, The Netherlands
Eur J Clin Pharmacol (2016) 72:719–723
DOI 10.1007/s00228-016-2038-9
adjusting the dosage of CsA are lacking. Based on our own
clinical observations and these earlier smaller studies, we hy-
pothesized that this interaction between CsA and imatinib
leads to increased concentrations of CsA requiring dose ad-
justment. Therefore, we assessed CsA-imatinib interaction in
patients after HSCT by measuring dose-corrected CsA con-
centrations before and after initiation of imatinib.
Methods
We performed a retrospective cohort study in CML and Ph+
ALL patients who underwent HSCT. Patients were selected
from a database of 44 patients, containing all patients under-
going HSCT between 2005 and 2015 in the Erasmus Medical
Center because of CML or Ph+ ALL. We used the electronic
patient records to scan the patients for eligibility and to collect
data.
The inclusion criteria were simultaneous use of oral CsA
and imatinib and at least one CsA concentration in the month
before and at least one CsA concentration after imatinib initi-
ation. The only exclusion criterion was use of azole antifun-
gals (i.e. fluconazole, voriconazole and itraconazole) only be-
fore or only after initiation of imatinib, because azole antifun-
gals are CYP3A4 and P-gp inhibitors and therefore increase
CsA concentrations during concomitant use [11]. Patients
were included if the azole antifungal was used during the
whole study period.
Taken into account the CsA intrapatient variability, we
aimed to collect for each patient five CsA trough concentra-
tions before and five trough concentrations after initiation of
imatinib treatment. The used target level for this indication
was 250–350 ng/mL. The CsA assay was performed using a
validated UPLC-MS/MS method, routinely used in our clinic.
The CsA concentration measurement was excluded from
the analysis if the CsA dosage used at that time point could not
be obtained from the patient records or if the treating physi-
cian had documented uncertainty regarding the time of drug
intake, i.e. whether the measured concentration was indeed a
trough level.
Analysis
We calculated the dose-corrected CsA concentration for each
concentration measurement by dividing the CsA concentra-
tion (ng/mL) by the CsA dosage (daily dose) used at that
moment. The average dose-corrected CsA concentration was
calculated for each patient before and after initiation of ima-
tinib. We compared these averages by using a paired sample t
test. We calculated the effect of different imatinib dosages on
dose-corrected CsA concentrations by comparing the differ-
ence between average dose-corrected CsA concentrations
before and during imatinib for each imatinib dosage using a
linear regression model. Significance was defined as p < 0.05.
No formal ethical approval was obtained since the research
was retrospective using anonymized data. All patients signed
informed consent when undergoing HSCT including informa-
tion about the use of anonymized medical data by scientists.
Results
We included 16 patients out of 44 patients: in five patients,
data (especially exact CsA doses; one patient lost to
follow-up) were missing, 18 patients did not receive imatinib
after HSCT (three died because of complications of HSCT, 13
switched to another tyrosine kinase inhibitor after HSCT due
to imatinib refractory disease), three patients did not receive
CsA at the moment imatinib was re-initiated and two patients
received an azole antifungal only after initiation of imatinib.
Table 1 shows the patient characteristics. On average, there
were 4.2 CsA concentration measurements both before and
after initiation of imatinib treatment. The first CsA measure-
ment taken into account was on average 20.4 days (standard
deviation (SD) 12.6) before initiation of imatinib and the last
measurement 21.8 days (SD 12.4) after (Table 2). In two pa-
tients, the imatinib dosage was changed during the study pe-
riod. All others used a stable daily dose of 400 or 600 mg.
The first CsA concentration after initiation of imatinib led
to a rise in CsA trough concentration above the target of
350 ng/mL in 10 out of 16 patients. After the first CsA con-
centration, CsAwas discontinued in one patient and the dose
was reduced in 12 patients. In the remaining three patients, the
CsA dose was reduced after the second CsA measurement
after initiation of imatinib. In all patients, dose reduction of
CsAwas necessary after initiation of imatinib.
The average dose-corrected CsA concentration significant-
ly increased during imatinib by 94 % (p < 0.001, range 16–
257 %) as shown for each patient in Fig. 1. Following dose
adjustments, the average CsA dosage was 27 % lower during
imatinib (p = 0.004, range 78 % lower–44 % higher). Overall,
despite dose adjustments, the average CsA concentrations
were 26 % higher during imatinib (p = 0.009, range 36 %
lower–81 % higher). The supra-therapeutic CsA concentra-
tions coincided with an increase of creatinine concentration
(range 13–64 μmol/L increase) at the next measurement after
initiation of imatinib in 13 out of 16 patients.
The mean variability in dose-corrected CsA concentrations
was lower before than after initiation of imatinib (ranges
shown in Table 2; p for difference in variability of
dose-corrected CsA concentrations = 0.085).
There was no significant difference in dose-corrected CsA
concentrations and the necessity of CsA dose adjustment be-
tween patients using 400 or 600 mg imatinib.
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Cyclosporine pharmacokinetics might be influenced by
other CYP3A4 substrates. The only CYP3A4 inhibitors used
in this population were antifungal agents know as ‘–azoles’.
Patients using voriconazole or fluconazole showed a rise in
dose-corrected CsA concentrations comparable to patients not
using these agents (as indicated with a symbol in Fig. 1).
Table 1 General characteristics




Diagnosis Donor Conditioning Imatinib
(mg)
1 M 17 66 98 ALL SIB Myeloablative 400
2 M 56 68.1 126 ALL MUD RIC 400
3 F 65 62 53 ALL MUD RIC 400b
4 M 17 65.8 70 ALL MUD Myeloablative 600
5 F 47 64.3 71 ALL SIB RIC 600
6 F 17 63.4 132 CML MUD Myeloablative 600
7 M 21 65.5 72 ALL UCB RIC 600
8 F 41 56 93 ALL UCB RIC 600c
9 F 58 80.4 84 CML MUD RIC 400
10 F 51 85.8 78 ALL SIB RIC 600
11 M 35 78.8 140 CML UCB RIC 400
12 F 57 64.1 83 CML UCB RIC 600
13 M 41 75 91 ALL SIB RIC 600
14 F 59 46.9 66 ALL MUD RIC 600
15 M 62 74.7 130 ALL MUD RIC 600
16 F 51 76.9 91 CML UCB RIC 400
M male, F female, CsA cyclosporine A, ALL acute lymphatic leukemia, CML chronic myeloid leukemia, SIB
sibling, MUD matched unrelated donor, UCB umbilical cord blood, RIC reduced intensity conditioning
aMeasured on the same day or less than 1 week before first included CsA measurement
b Dose switch to 600 mg from 3rd CsA concentration
c Dose switch to 400 mg from 4th CsA concentration
Table 2 Dosages and concentrations of CsA before and after initiation of imatinib
Patient Number of CsA concentrations Number of daysa Mean daily CsA dosage (mg) (range) Mean CsA concentration (ng/mL) (range)
Before During Before After Before After Before After
1 5 5 42 42 150 (150) 95 (75–125) 285 (221–355) 339 (272–513)
2 2 2 2 3 225 (200–250) 50 (25–75) 358 (308–408) 228 (161–294)
3 5 5 9 14 150 (150) 80 (25–150) 263 (214–299) 411 (273–586)
4 2 5 7 38 138 (125–150) 115 (100–150) 239 (192–285) 289 (183–438)
5 5 5 23 21 200 (200) 120 (100–200) 283 (212–321) 409 (242–847)
6 5 5 22 9 225 (200–250) 160 (125–175) 259 (209–333) 315 (291–376)
7 3 4 8 14 175 (150–200) 175 (150–200) 341 (205–572) 453 (311–576)
8 5 5 24 25 125 (100–175) 130 (112.5–150) 212 (107–361) 352 (118–696)
9 5 5 28 16 190 (175–212.5) 148 (125–212.5) 283 (177–438) 271 (194–338)
10 3 5 14 18 300 (250–400) 180 (150–250) 342 (250–469) 345 (237–437)
11 4 1 12 NA 156 (100–225) 225 (225) 205 (159–280) 351 (351)
12 5 2 15 4 290 (225–325) 300 (250–350) 336 (142–561) 608 (537–678)
13 5 5 19 21 165 (150–175) 105 (75–175) 316 (232–429) 421 (332–615)
14 3 5 24 31 150 (150) 95 (50–175) 258 (236–284) 399 (207–542)
15 5 4 28 36 155 (125–175) 81 (50–100) 304 (195–495) 268 (161–393)
16 5 4 49 35 105 (75–125) 69 (25–125) 176 (134–234) 158 (77–315)
a Between first CsA measurement and initiation of imatinib, respectively between initiation of imatinib and last CsA measurement
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However, the rise in the only patient using voriconazole (the
stronger CYP3A4 inhibitor) was less pronounced. One patient
used different fluconazole dosages before and after initiation
of imatinib; however, his CsA dose-corrected concentration
was comparable to those of other patients on fluconazole or
voriconazole. None of the patients used another CYP3A4
substrate or inhibitor, such as diltiazem, verapamil or St
John’s wort.
Discussion
In this retrospective cohort study, it is shown that imatinib
significantly increases CsA exposure in CML and Ph+ ALL
patients after HSCT, leading to an average dose reduction of
27 % to reach similar CsA concentrations. Therefore,
pre-emptive CsA dose reduction at the time of initiation of
imatinib treatment and subsequent intensive CsA concentra-
tion monitoring is recommended in order to avoid additional
CsA-related toxicity, such as nephrotoxicity which was also
seen in this population.
Our results confirm earlier preliminary findings in case
reports and one case series [8–10]. Two studies found no in-
crease in CsA exposure during imatinib, but these studies both
had important limitations: in the first study, the participants
received a subtherapeutic imatinib dosage of 200 mg, while in
the second study CsA dosages were not taken into account [5,
12].
In a recent case series in six children, the pre-emptive CsA
dose reduction following imatinib co-treatment was suggested
to be 40 % [10]. In our study, the average dose reduction was
27 %. There was a substantial interpatient variability in
dose-corrected CsA concentrations after initiation of imatinib.
CsA is well known to have a large interpatient as well as
intrapatient variability caused by different factors such as dif-
ferences in nutrition and genetic variability [1, 13]. We aimed
to minimize the effect of intrapatient variability by aiming to
collect five CsA concentrations before and five CsA concen-
trations after initiation of imatinib. The intrapatient variability
in dose-corrected CsA concentrations was larger after initia-
tion of imatinib than before initiation (p = 0.085). This em-
phasizes the importance of intensive CsA concentration mon-
itoring after initiation of imatinib. These findings did not in-
fluence our conclusion, because it does not explain the signif-
icant increase in average dose-corrected CsA concentrations.
The increase in CsA concentrations coincided with an in-
crease of creatinine concentration at the next measurement
after initiation of imatinib. This study was underpowered for
this endpoint. However, the observed rise in creatinine con-
centrations does emphasize the importance of avoiding
supra-therapeutic CsA exposure. In two patients, CsA treat-
ment was discontinued or interrupted after initiation of ima-
tinib due to progressive renal insufficiency.
Patients using CYP3A4 inhibitors such as voriconazole or
fluconazole showed a rise in dose-corrected CsA concentra-
tions comparable to patients not using these agents (as indicated
with an asterisk in Fig. 1). However, the rise in the only
patient using voriconazole (the stronger CYP3A4 inhibitor)
was less pronounced.
The mechanism of the pharmacokinetic interaction be-
tween CsA and imatinib is most likely inhibition of
CYP3A4 activity by imatinib. Potentially, the interaction
may also be explained by increased bioavailability of CsA
due to imatinib-induced inhibition of the P-glycoprotein efflux
pump in enterocytes [14].We anticipated that concomitant use
of other CYP3A4 substrates might influence the result of
adding imatinib to CsA [15]. Four patients used voriconazole
(n = 1) or fluconazole (n = 3), both before and after initiation
of CsA. Although we expected that in these patients the phar-
macokinetic interaction between CsA and imatinib would be
less pronounced, we did see a rise in dose-corrected CsA
concentrations comparable to patients not using these agents
(as indicated with a symbol in Fig. 1). However, the only
patient with voriconazole co-treatment (the stronger
CYP3A4 inhibitor) had a rise in average dose-corrected CsA
concentration from only 1.48 before to 1.86 after initiation of
imatinib.
The strength of our study is that it is the first study in a
relatively large group of HSCT patients aged >16 years old
that shows increased CsA exposure after initiation of imatinib.
A potential limitation is the retrospective observational
study design. However, the medication data and laboratory
measurements were well documented in the patient files. In
our view, the sample size is sufficiently large to draw conclu-
sions and recommend dose reductions when imatinib is added
to CsA treatment, especially since the effect was consistently
Fig. 1 Average dose-corrected CsA concentration before and after
initiation of imatinib. The average of all ratios of CsA concentration
(ng/mL) divided by the used daily dose of CsA on that day (mg) before
and after initiation of imatinib. Patients using *fluconazole 50 mg once
daily; #fluconazole 400 mg once daily; ^voriconazole 200 mg twice daily,
all the same dose before and after initiation of imatinib; +fluconazole
400 mg once daily before and 200 mg once daily after initiation of
imatinib
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observed in all patients. Furthermore, the mechanism for the
pharmacokinetic interaction is plausible.
Nowadays, tacrolimus is also used as immunosuppressive
drug instead of CsA [16]. Since tacrolimus is also a substrate
of CYP3A4 and P-gp, it will be interesting to study the effect
of initiation of imatinib for tacrolimus concentrations as well.
Since in our center CsA is the first choice for GvHD preven-
tion or treatment, we could not investigate this further.
In conclusion, imatinib increases CsA exposure in CML
and Ph+ ALL patients after HSCT leading to increased CsA
concentrations requiring an average dose reduction of 27 %.
Therefore, we recommend a pre-emptive CsA dose reduction
of at least 25 % when initiating imatinib, to prevent CsA
toxicity. Moreover, CsA concentrations should be closely
monitored, to avoid underexposure or overexposure.
A good option would be perform therapeutic drug moni-
toring on the day of initiation of imatinib to enable dose ad-
justment by Bayesian modeling [17].
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